Stryker to launch Tritanium C Anterior Cervical Cage in Q4 2017: 5 insights

Mackenzie Garrity -   Print  |

Stryker showcased its 3-D Tritanium C Anterior Cervical Cage at the Congress of Neurological Surgeons annual meeting. The company plans to launch the fusion device next quarter.

Here are five insights:


1. The Tritanium C Anterior Cervical Cage is an interbody fusion device designed for use in the cervical spine and part of Stryker's Tritanium In-Growth Technology, a porous titanium material designed for bone in-growth and biological fixation.


2. To develop the fusion implant, Stryker used AMagine, its proprietary approach to create implants using 3-D printing. The Tritanium is designed to wick or retain fluid in comparison to traditional titanium.


3. The Tritanium C Anterior Cervical Cage features an open central graft window and lateral windows to reduce cage stiffness and minimize subsidence. The graft window also allows for graft containment.


4. Additionally, the cage has serrations on the superior and inferior surfaces designed to allow for bidirectional fixation and to maximize surface area for endplate contact with the cage.


5. Stryker received FDA clearance for the cage in September 2017 and offers the cage in various footprints, heights and lordotic angles to adapt to a range of patients.


More articles on devices:
DePuy Synthes, Stryker & more: 5 device company mergers, acquisitions & agreements
Mainstay Medical appoints CEO Jason Hannon to board of directors: 4 takeaways
Synaptive Medical releases 2nd-generation optics platform for BrightMatter: 6 things to know


© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers